Back to Journals
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Vice Chairman, Department of Medicine, Warren, University of Oklahoma Health Science Center, United States
Editor-in-Chief: Professor Ming Zou
Dr Zou is professor of biomedical sciences, director at the Center of Molecular and Translational Medicine and associate vice president for research at Georgia State University.
Dr Zou earned his medical degree at the Hubei Medical University at Xianning, China and his PhD degree in the University of Konstanz, Germany. He worked as assistant professor in the Boston University School of Medicine and associate professor in the University of Tennessee. He became professor of biochemistry and medicine in the University of Oklahoma Health Science Center in 2006.
Dr Zou has served on several national and international study panels such as the National Institutes of Health, American Diabetes Association, American Heart Association, Chinese National Science Foundation, etc. In 2008 he was elected to the American Society for Clinical Investigation, membership in which reflects accomplishments by its members at an early stage in their careers and one of the United States’ oldest honor societies of physician-scientists.
Dr Zou is recognized internationally as an expert in diabetes and diabetes-related cardiovascular complications. He is the author of more than 100 journal articles and book chapters. He is the editorial members for over ten journals and reviewer for over 30 journals, including Diabetes, the Journal of Clinical Investigation, Journal of Biological Chemistry, Circulation, Circulation Research, and the New England Journal of Medicine.
Associate Editor: Steven F. Abcouwer
Dr. Abcouwer is currently a Professor of Ophthalmology and Visual Sciences at the University of Michigan Medicine Kellogg Eye Center. He trained as a chemical engineer at the University of Missouri-Columbia, specializing in biochemical engineering during PhD training at the University of Houston. He gravitated toward biomedical research as he conducted postdoctoral training at Monsanto Heath Sciences, studying therapeutic approaches to inhibit tumor invasion and metastasis. As a junior faculty member at Harvard Medical School Department of Surgery at the Massachusetts General Hospital he cloned a novel human glutaminase gene and identified the regulatory elements in the rat glutamine synthetase gene. Then, as a faculty member at the University of New Mexico School of Medicine, Department of Biochemistry and Molecular Biology he discovered the role of activating transcription factor 4 in regulation of vascular endothelial growth factor (VEGF) gene expression. While at Penn State University College of Medicine, Departments of Surgery, Ophthalmology and Physiology he studied neuronal death mechanisms and conducted preclinical testing of therapeutics in rodent models of diabetic retinopathy. He joined the University of Michigan in 2010. He is currently Co-Principal Investigator of two National Eye Institute-funded R01 research grants exploring pathological mechanisms of diabetic retinopathy, is Co-Principal Investigator for a National Institute of Diabetes, Digestive and Kidney Diseases-funded R24 grant examining metabolic changes in diabetic complications-prone tissues caused by diabetes, is Principal Investigator for several research contracts with pharmaceutical companies and is the Director of the Molecular Biology Module of the National Eye Institute-funded Kellogg Eye Center Vision Research Core Facility. Dr. Abcouwer has sat on numoersour national and international grant review committes and is currently is a regular member of the National Institutes of Heath Diseases and Pathophysiology of the Visual System Study Section. He serves on the editorial board of several scientific journals. His current research interests include neurodegeneration and vascular dysfunction in diabetic retinopathy, the role of inflammation in retinal vascular dysfunction, and mechanisms controling retinal vascular develoment.
Cell and Molecular Biology, Madras Diabetes Research Foundation, India
Associate Editor: Dr Balasubramanyam
Dr.Balasubramanyam is at present Dean of Research Studies & Senior Scientist at the Madras Diabetes Research Foundation, Chennai, India. He obtained his PhD degree in 1987 from Sri Venkateswara University, Tirupati. During 1991 to 1995, he worked as a Post-Doctoral Scientist at the Hypertension Research Center of the University of Medicine and Dentistry of New Jersey (UMDNJ), Newark, USA on “Cell signaling & Molecular medicine aspects with special reference to diabetes’. During 1996-99, he served as a faculty at the Center for Biotechnology, Anna University, Chennai. He joined the Madras Diabetes Research Foundation in 1999 and instrumental in many of its academic developments including infrastructure for basic science and translational studies. He has over 115 original research publications and many awards to his credit.
Dr.Balasubramanyam’s specialization and research interests include: Disease-Biology and molecular medicine with special reference to diabetes and its vascular complications, metabolic syndrome & obesity, molecular mechanisms of accelerated ageing, redox signaling and ‘biomarkers’ of oxidative stress, role of microinflammation, ER stress, telomere biology, the gut (microbiota) connection to diabetes, proteomics/epigenetics/miRNA profiling in fat and skeletal muscle with special reference to insulin signaling and drug discovery, metabolomics, exposomics, stem cell research, role of endocrine disruptors, bio-prospecting molecular targets of herbal action and development of cell-based, high-throughput assays as well as point-of-care (POC) medical devices.
Dr.Balasubramanyam is also an elected Member of the Asia-Pacific International Molecular Biology Network (A-IMBN). He has recently received the prestigious Endeavour Executive Fellowship from the Education Department of Govt. of Australia. He serves as an Expert Committee member in many funding agencies of Govt. of India. At national and international levels, he serves as an expert member of multiple grant review panels and on the editorial advisory boards of multi-disciplinary journals.
Associate Editor: Antonio Brunetti
Dr. A. Brunetti is a Professor in Endocrinology at the University “Magna Græcia” of Catanzaro, Italy. He graduated in medicine and specialized in Endocrinology and Metabolism at the University of Catania, Italy. In 1992 he obtained the PhD degree in Endocrine and Metabolic Sciences from the University of Naples, Italy, while he was working at the Division of Diabetes & Endocrine Research, University of California San Francisco (UCSF), USA. During his PhD programme at UCSF, Prof. Brunetti led and was the principal investigator of a series of studies that helped to clarify most of the molecular mechanisms involved in insulin action and the regulation of insulin receptor gene expression in muscle, liver and fat.
Over the past 15 years his research activity has mostly focused on the molecular genetics of insulin resistance and type 2 diabetes, followed by the discovery of a novel mechanism for insulin resistance in a subset of diabetic patients. These studies have helped to identify critical components of the transcriptional machinery that governs insulin receptor gene expression, indicating that defects in the architectural factor HMGA1 (the most important among these components) may cause “HMGA1opathy”, a novel insulin resistance subphenotype observed in patients with either rare forms of insulin resistance or common type 2 diabetes. The results obtained from these studies have provided insights into previously unexplored aspects of insulin resistance and have been presented in various international conferences and published in leading peer reviewed journals.
His current research includes the study of chronic inflammation and hypoxia in fat and their role in the development of obesity-related insulin resistance in the effort to identify new biological targets and biomarkers of early disease. The actual researching activity is also centered on the study of gestational diabetes mellitus (GDM) and the identification of early predictors of GDM and glucose intolerance during pregnancy.
From 2008 to 2016 he coordinated the PhD programme in Endocrine-Metabolic and Nutritional Sciences at the University “Magna Græcia” of Catanzaro. Currently he is a member of the PhD programme in Biomarkers of chronic and complex diseases, and Director of the Operative Unit of Endocrinology and Metabolism at the Azienda Ospedaliero-Universitaria “Mater Domini”, University “Magna Græcia” of Catanzaro, Italy. At national and international levels, he has served as member of multiple editorial boards, and is an active member of various professional societies.
Medical Sciences, Chang Jung Christian University, Taiwan
Associate Editor: Juei-Tang Cheng
Dr. Cheng is a chair-professor at the Chang Jung Christian University and he also serves as a Senior Investigator in Chi-Mei Medical Center. During his PhD thesis research in pharmacology at Shizuoka Pharmaceutical College in Japan, he demonstrated that calcium-induced calcium release in smooth muscle. Then, he was invited as an associate professor at Tajen Pharmaceutical College in Taiwan. He found a nature fruit Guava in the alleviation of diabetic disorders. In 1986, he moved to the National Cheng Kung University to serve as an associate professor in pharmacology. He continued his favorite target, effects of natural products on diabetic complications. Depending on several findings, he promoted to the professor in the same university. Therefore, Dr. Cheng directed graduate students to investigate the pathophysiology of diabetes and the role of peptides in neuroendocrinology. He characterized the mediation neuropeptide Y in diabetic disorders and established the major role of beta-endorphin in metabolic regulation. In 1996, Dr. Cheng became the chairman of the Research Center for Traditional Chinese Medicine in his university. He used herbal products to demonstrate several findings in the alleviation of diabetic disorders. Therefore, Dr. Cheng got the Fellowship (FCP) from the American College of Clinical Pharmacology. He developed the role of opioid mu-receptors in the metabolic regulation and suggested endogenous receptors are helpful in the regulation of metabolism. Additionally, mediation of endogenous imidazoline receptors in diabetes has also been demonstrated in several publications. Since 2009, Dr. Cheng was retired and moved to the present university. His current research includes a systems biology approach to study the processes of metabolic disorders in efforts to identify new targets for the handling of diabetes and/or metabolic syndrome.
Dr. Cheng has been an active member of the American Diabetes Association (ADA) and New York Academy of Sciences, where he has been involved in the development of basic research to assist handling of metabolic disorders. At national and international levels, he has served as a member of grant review panels and on the editorial advisory boards of multiple journals.
Department of Internal Medicine, Aristotle University of Thessaloniki, Greece
Associate Editor (Greece): Doctor Konstantinos Tziomalos
Konstantinos Tziomalos is Assistant Professor of Internal Medicine at the First Propedeutic Department of Internal Medicine of the Medical School, Aristotle University of Thessaloniki, in AHEPA Hospital, Thessaloniki, Greece. He completed his residency at the Second Propedeutic Department of Internal Medicine of the Medical School, Aristotle University of Thessaloniki, in Hippokration Hospital, Thessaloniki, Greece. He then served as a clinical research fellow at the Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Campus, University College London Medical School, University College London, UK and as a post-doctorate research fellow at the Stem Cell Institute and Cardiovascular Research Laboratory, Division of Cardiology, Miller School of Medicine, University of Miami, USA. His research interests include dyslipidemia, stroke and cardiovascular disease prevention. He has authored more than 300 peer-reviewed scientific articles, which have received more than 6000 citations.
Julien S Baker, Professor, Director of Research, Institute of Clinical Exercise and Health Sciences, Applied Physiology Research Laboratory, School of Health and Life Sciences, University of the West of Scotland, Scotland
Abdulbari Bener, Advisor to WHO, Professor of Public Health, Dept. of Biostatistics & Medical Informatics, Cerrahpaşa Faculty of Medicine, Istanbul University, Turkey
Baptist Gallwitz, Professor, Deputy Director, Medical Clinic IV, University Hospital Tübingen, Tübingen, Germany
Claes-Göran Östenson, Professor of Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Amer Rajab, Department of Surgery, Ohio State University Medical Center, Columbus, Ohio, USA
Amy Jo Riggs, Health and Kinesiology Department, Georgia Southern University, GA, USA
Kerry Stewart, Professor of Medicine, Director, Clinical and Research Exercise Physiology, John Hopkins University School of Medicine, MD, USA
Chaowu Xiao, Adjunct Professor, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Canada
Wen-Zhu Yang, Lethbridge Research Centre, Agriculture and Agri-Food Canada, Canada
Allan Z. Zhao, Ph.D., Member, the National 1000 Talents Program; Distinguished Professor, The Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, People's Republic of China